Earnings History Data for Alzamend Neuro (ALZN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Alzamend Neuro

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume	Top Mover
11-12-2024	PM		ALZN	Alzamend Neuro	5.00	-0.40	-2.38	0.00	Alzamend Neuro GAAP EPS of -$0.40 beats by $0.37 [12/12/2024 8:06 AM]	1.20	0.0 (0.00%)	1.19	-0.01 (-0.83%)	1.06 - 15.06	52,792	140,000	1,583
Alzamend Neuro GAAP EPS of -$0.40 beats by $0.37 [12/12/2024 8:06 AM] Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs [2024-12-12 08:00AM]